A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME

Clinical trial NCT06957080 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06957080
Sponsor: EyeBiotech Ltd.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Diabetic Macular Edema (DME)

Start date: 2025-04-16
Primary completion: 2027-03-01
Enrollment: 1054

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.